1. Home
  2. ICUI vs SRRK Comparison

ICUI vs SRRK Comparison

Compare ICUI & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ICUI
  • SRRK
  • Stock Information
  • Founded
  • ICUI 1984
  • SRRK 2012
  • Country
  • ICUI United States
  • SRRK United States
  • Employees
  • ICUI N/A
  • SRRK N/A
  • Industry
  • ICUI Medical/Dental Instruments
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ICUI Health Care
  • SRRK Health Care
  • Exchange
  • ICUI Nasdaq
  • SRRK Nasdaq
  • Market Cap
  • ICUI 3.8B
  • SRRK 4.2B
  • IPO Year
  • ICUI 1992
  • SRRK 2018
  • Fundamental
  • Price
  • ICUI $141.97
  • SRRK $36.00
  • Analyst Decision
  • ICUI Buy
  • SRRK Strong Buy
  • Analyst Count
  • ICUI 4
  • SRRK 7
  • Target Price
  • ICUI $199.67
  • SRRK $40.43
  • AVG Volume (30 Days)
  • ICUI 237.9K
  • SRRK 827.5K
  • Earning Date
  • ICUI 05-06-2025
  • SRRK 05-06-2025
  • Dividend Yield
  • ICUI N/A
  • SRRK N/A
  • EPS Growth
  • ICUI N/A
  • SRRK N/A
  • EPS
  • ICUI N/A
  • SRRK N/A
  • Revenue
  • ICUI $2,382,046,000.00
  • SRRK N/A
  • Revenue This Year
  • ICUI N/A
  • SRRK N/A
  • Revenue Next Year
  • ICUI $3.00
  • SRRK $617.74
  • P/E Ratio
  • ICUI N/A
  • SRRK N/A
  • Revenue Growth
  • ICUI 5.44
  • SRRK N/A
  • 52 Week Low
  • ICUI $93.36
  • SRRK $6.76
  • 52 Week High
  • ICUI $196.26
  • SRRK $46.98
  • Technical
  • Relative Strength Index (RSI)
  • ICUI 31.62
  • SRRK 41.79
  • Support Level
  • ICUI $135.77
  • SRRK $35.03
  • Resistance Level
  • ICUI $145.58
  • SRRK $37.89
  • Average True Range (ATR)
  • ICUI 7.07
  • SRRK 2.30
  • MACD
  • ICUI -1.55
  • SRRK -0.00
  • Stochastic Oscillator
  • ICUI 21.09
  • SRRK 18.83

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Share on Social Networks: